Although SGLT2 inhibitors and GLP-1RAs are recommended in patients with type 2 diabetes and CVD, or at high/very high CVD risk, to reduce cardiovascular events, in our study only 6.0% (n = 4) of eligible patients are receiving these therapies, which is coincident with other studies [29,30]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.